Genetic polymorphisms of the CYP3A4, CYP3A5, CYP3A7 and CYP1A2 among the Jordanian population

Environmental Toxicology and Pharmacology

Volumn 34, Issue 1, 2012, Pages 23-33

  Salameh, Ghada ^a   Hadidi, Kamal Al ^a   Khateeb, Mohammad El ^a,b  

^a UNIVERSITY OF JORDAN   (Jordan)

^b Endocrinology and Genetics   (Jordan)

Author keywords

Allele frequency; Biomarkers; Cytochrome P450

Indexed keywords

CYTOCHROME P450 1A2; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; CYTOCHROME P450 3A7; GENOMIC DNA;

AFRICAN AMERICAN; ALLELE; ARTICLE; ASIAN; CAUCASIAN; CHINESE; CONTROLLED STUDY; ETHNIC DIFFERENCE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HISPANIC; HUMAN; JAPANESE; JORDAN; MIDDLE EAST; NEGRO; POPULATION GENETICS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP3A; GENE FREQUENCY; GENOTYPE; HUMANS; JORDAN; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH;

EID: 84858717350     PISSN: 13826689     EISSN: 18727077     Source Type: Journal    
DOI: 10.1016/j.etap.2012.01.006     Document Type: Article

References (50)

1. Ando Y., Tateishi T., Sekido Y., Yamamoto T., Satoh T., Hasegawa Y., Kobayashi S., Katsumata Y., Shimokata K., Saito H. Re: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J. Natl. Cancer Inst. 1999, 91(18):1587-1588.
2. Bilgen T., Tosun O., Luleci G., Keser I. Frequencies of four genetic polymorphisms in the CYP1A2 gene in Turkish population. Russ. J. Genet. 2008, 44(8):989-992.
3. Belitsky G.A., Yakubovskaya M.G. Genetic polymorphism and variability of chemical carcinogenesis. Biochemistry-Moscow 2008, 73(5):543-554.
4. Bozina N., Bradamante V., Lovric M. Genetic polymorphism of metabolic enzymes P450 (CYP) as a susecptability factor for drug response, toxicity and cancer risk. Arch. Ind. Hyg. Toxicol. 2009, 60:217-242.
5. Burk O., Tegude H., Koch I., Hustert E., Wolbold R., Glaeser H., Klein K., Fromm M.F., Nuessler A.K., Neuhaus P., Zanger U.M., Eichelbaum M., Wojnowski L. Molecular mechanisms of polymorphic CYP3A7 expression in adult human liver and intestine. J. Biol. Chem. 2002, 277(27):24280-24288.
6. Burk A., Wojnowski L. Cytochrome P450 3A and their regulation. N-S. Arch. Pharmacol. 2004, 369:105-124.
7. Chen X., Wang H., Zhou G., Zhang X., Dong X., Zhi L., Jin L., He F. Molecular population genetics of human CYP3A locus: signatures of positive selection and implications for evolutionary environmental medicine. Environ. Health Perspect. 2009, 117:1541-1548.
8. Chida M., Yokoi T., Fukui T., Kinoshita M., Yokota J., Kamataki T. Detection of three genetic polymorphisms in the 5'-flanking region and intron 1 of human CYP1A2 in the Japanese population. Jpn. J. Cancer Res. 1999, 90:899-902.
9. Chou F.C., Tzeng S.J., Huang J.D. Genetic polymorphism of cytochrome P450 in Chinese. Drug Metab. Dispos. 2001, 29(9):1205-1209.
10. Denisov L.G., Makris T.M., Sligar S.G., Schlichting L. Structure and chemistry of cytochrome P450. Chem. Rev. 2005, 105:2253-2277.
11. Dostalek M., Court M.H., Yan B., Akhlaghi F. Significantly reduced cytochrome P450 3A4 expression and activity in liver from humans with diabetes mellitus. Br. J. Pharmacol. 2011, 163:937-947.
12. Ghobti R., Christensen M., Roh H.K., Ingelmen-sundberg M., Aklillu E., Bertilsson L. Comparsions of CYP1A2 genetic polymorphism, enzyme activity and genotype-phenotype relationship in Swedes and Korean. Eur. J. Clin. Pharmacol. 2007, 63:537-546.
13. Gonzalez F.J. Cytochrome P450 in humans. Cytochrome P450 1993, 239-249. Springer, Berlin. J.B. Schenkman, H. Greim (Eds.).
14. Guengerich F.P. Cytochrome P450s and other enzymes in drug metabolism and toxicity. AAPS J. 2006, 8(1):101-111.
15. Guengerich F.P. Human cytochrome P450 enzymes. Cytochrome P450, Structure, Mechanism and Biochemistry 2005, 377-530. Kluwer Academic-Plenum Publishing, New York. P.O. Ortiz De Montellano (Ed.).
16. Guengerich F.P. Cytochrome P450 and chemical toxicology. Chem. Res. Toxicol. 2008, 21:70-83.
17. Gunes A., Dahl M.L. Variation in CYP1A2 activity and its clinical implications: influence of environmental factors and genetic polymorphisms. Pharmacogenomics J. 2008, 9(5):625-637.
18. Hamdane D., Zhang H., Hollenberg P. Oxygen activation by cytochrome P450 monooxygenase. Photosynth. Res. 2008, 98:657-666.
19. Hamdy S.I., Hiratsuka M., Narahara K., Endo N., El-Enany M., Moursi N., Ahmed M.S.E., Mizugaki M. Genotyping of four genetic polymorphisms in the CYP1A2 gene in the Egyptian population. Br. J. Clin. Pharmacol. 2003, 55:321-324.
20. Hasler J.A., Estabrook R., Michael M., Pikuleva I., Waterman M., Capdevila J., Holla V., Helvig C., Falck J.R., Farell G., Kaminsky L.S., Spivack S.D., Boiter E., Beaune P. Human Cytochrome P450. Mol. Aspects Med. 1999, 20:1-137.
21. Hong J.Y., Yang C.S. Genetic polymorphism of cytochrome P450 as a biomarker of susceptibility to environmental toxicity. Environ. Health Perspect. 1997, 105(4):759-762.
22. Hustert E., Haberl M., Burk O., Wolbold R.H., Klein Y.Q., Nuessler K., Neuhaus A.C., Klattig P., Eiselt J., Kosh R., Zibat I., Brockmoller A., Halpert J., Zanger J., Wojnowski U.M.L. The genetic determinant of the CYP3A5 polymorphism. Pharmacogenetics 2001, 11(9):773-779.
23. Irigaray P., Belpomme D. Basic properties and molecular mechanisms of exogenous chemical carcinogens. Carcinogenesis 2010, 31(2):135-148.
24. King B.P., Leathart J.B.S., Mutch E., Williams F.M., Daly A.K. CYP3A5 phenotype-genotype correlations in a British population. J. Clin. Pharmacol. 2003, 55:625-629.
25. Kuehl P., Zhang J., Lin Y., Lamba J., Assem M., Schuetz J., Watkins P.B., Daly A., Wrighton S.A., Hall S.D., Maurel P., Relling M., Brimer C., Yasuda K., Venkataramanan R., Storm S., Thummel K., Boguski M.S., Shuetz E. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. 2001, 27:383-391.
26. Lamba J.K., Lin Y.S., Thummel K., Daly A., Watkins P.B., Strom S., Zhang J., Schuetz E.G. Common allelic variants of P4503A4 and their prevalence in different populations. Pharmacogenetics 2002, 12:121-132.
27. Leeder J.S., Gaedigk R., Marcucci K.A., Gaedigk A., Vyhlidal C.A., Schindel B.P., Pearce R.E. Variability of CYP3A7 expression in human fetal liver. J. Pharmacol. Exp. Ther. 2005, 314(2):626-635.
28. Lee S.J., Goldstein J.A. Functionally defective or altered CYP3A4 and CYP3A5 single nucleotide polymorphisms and their detection with genotyping tests. Pharmacogenomics J. 2005, 6(4):357-371.
29. Lewis D.F.V., Jacobs M.N., Dickins M. Compound lipophilicity for substrate binding to human P450s in drug metabolism. DDT 2004, 9(12):530-537.
30. Nakajima M., Yokoi T., Mizutani, Kinoshita M., Funayama M., Kamataki T. Genetic polymorphism in the 5'-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. J. Biochem. (Tokyo) 1999, 125:803-808.
31. Pelkonen O., Turpeinen M., Hakkola J., Honkakoski P., Hukkanen J., Raunio H. Inhibition and induction of human cytochrome P450 enzymes: current status. Arch. Toxicol. 2008, 82:667-715.
32. Rahmioglu N., Heaton J., Clement G., Gill R., Surdulescu G., Zlobecka K., Hodgkiss D., Ma Y., Hider R.C., Smith N.W., Ahmadi K.R. Genetic epidemiology of induced CYP3A4 activity. Pharmacogenet. Genom. 2011, 21(10):642-651.
33. Rebbeck T.R., Jaffe J.M., Walker M.H., Wein A.J., Malkowicz S.B. Modification of clinical presentation of prostate tumors by a novel variant in CYP3A4. J. Natl. Cancer Inst. 1998, 90(16):1225-1229.
34. Rodriguez-Antona C., Ingelman-Sundberg C. Cytochrome P450 pharmacogenetics and cancer. Oncogene 2006, 25:1679-1691.
35. *0 in prostate cancer. Urol. Oncol. 2011, 29:654-663.
36. Roy J.N., Lajoie J., Zijenah L.S., Barama A., Poirier C., Ward B.J., Roger M. CYP3A5 genetic polymorphisms in different ethnic populations. Drug Metab. Dispos. 2005, 33(7):884-887.
37. Sachse C., Bhambra U., Smith G., Lightfoot T.J., Barrett J.H., Scollay J., Garner R.C., Boobies A.R., Wolf C.R., Gooderham N.J. Polymorphisms in the cytochrome P450 CYP1A2 gene (CYP1A2) in colorectal cancer patients and controls: allele frequencies, linkage disequilibrium and influence on caffeine metabolism. J. Clin. Pharmacol. 2003, 55:68-76.
38. Shimada T., Yamazaki H., Mimura M., Inui Y., Guengerich F.P. Interindividaul variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 1994, 270(1):414-423.
39. *1C allele. Pharmacogenet. Genom. 2005, 15:625-631.
40. Smit P., Van Schaik R.H.N., Van der Werf M., Van den Beld A.W., Koper J.W., Lindemans J., Pols H.A.P., Brinkmann A.O., De Jong F.H., Lamberts S.W.J. A common Polymorphism in the CYP3A7 gene is associated with a nearly 50% reduction in serum dehydroepiandrosterone sulfate levels. J. Clin. Endocrinol. Metab. 2005, 90(9):5313-5316.
41. Tayeb M.T., Clark C., Sharp L., Haites N.E., Rooney P.M., Payne G.I., McLeod S.L.H.L. CYP3A4 promoter variant is associated with prostate cancer risk in men with benign prostate hyperplasia. Oncol. Rep. 2002, 9:653-655.
42. Todesco L., Török M., Krähenbühl S., Wenk M. Determination of -3858G→A and -164C→A genetic polymorphisms of CYP1A2 in blood and saliva by rapid allelic discrimination: large difference in the prevalence of the -3858G→A mutation between Caucasians and Asians. Eur. J. Clin. Pharmacol. 2003, 59(4):343-346.
43. Van Schaik R.H.N., Van Der Heiden I.P., Van der Anker J.N., Lindemans J. CYP3A5 variant allele frequency in Dutch Cucasians. Clin. Chem. 2002, 48(10):1668-1671.
44. Wijnen P.A., Op den Buijsch R.A., Drent M., Kuijpers P.M., Neef C., Bast A., Bekers O., Koek G.H. the prevalence and clinical relevance of cytochrome P450 polymorphisms. Aliment Pharmacol. Ther. 2009, 26:211-219.
45. Wojnowski L., Hustert E., Klein K., Goldammer M., Haberl M., Kitcheners J., Koch I., Klattig J., Zanger U., Brockm" oller J. Re: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J. Natl. Cancer Inst. 2002, 94(8):630-631.
46. Wojnowski L., Turner P.C., Pedersen B., Hustert J.B., Mendey M., Whittle H.C., Kirk G., Wild C.P. Increased levels of aflatoxin-albumin adducts are associated with CYP3A5 polymorphisms in The Gambia, West Africa. Pharmacogenetics 2004, 14:691-700.
47. Yi B., Yang J.Y., Yang M. Past and future applications of CYP450-genetic polymorphisms for biomonitoring of environmental toxicants. J. Environ. Sci. Health C 2007, 25:353-377.
48. Zhou S.F. Drugs behave as substrates inhibitors and inducers of human cytochrome P450 3A4. Curr. Drug Metab. 2008, 9(4):310-322.
49. Zhao H.H., Han X.M. Polymorphism of CYP450 and cancer susceptibility. Acta Pharm. Sin. 2000, 21(8):673-679.
50. Zhou S.F., Yang L.P., Zhou Z.W., Chan E. Insights into substrate specificity, inhibitors, regulation, and polymorphisms and the clinical impact of human cytochrome P450 1A2. AAPS J. 2009, 11(3):481-494.